Wyeth Duract launch ads claim superiority to Ultram, herald nonscheduled status.
WYETH DURACT LAUNCH TOUTS SUPERIORITY TO J&J's ULTRAM in a six-page journal advertisement pre-cleared by FDA. The ad launching the non-steroidal anti-inflammatory drug appeared in the New England Journal of Medicine and the Journal of the American Medical Association. "More power than Ultram 100 mg...in a single-dose study of oral surgery," the ad states. The ad references an unpublished study comparing Duract (bromfenac), Ortho-McNeil's Ultram (tramadol) and placebo conducted by SciRex in Austin, Texas. The study was submitted with the NDA but was not included in Wyeth- Ayerst's Duract labeling. The ad footnotes that the data is on file at Wyeth.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth